Skip to main content

Advertisement

SpringerLink
Log in

Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7(6):441–453

    Article  CAS  PubMed  Google Scholar 

  2. Jiang Q, Li Z, Qin Y et al (2022) Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol 15(1):113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dhillon S (2022) Olverembatinib: First Approval. Drugs 82(4):469–475

    Article  CAS  PubMed  Google Scholar 

  4. Liu X, Wang G, Yan X et al (2019) Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci 9:88

    Article  PubMed  PubMed Central  Google Scholar 

  5. Valentin R, Grabow S, Davids MS (2018) The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood 132(12):1248–1264

    Article  CAS  PubMed  Google Scholar 

  6. Carter BZ, Mak PY, Mu H et al (2016) Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med 8(355):355ra117

    Article  PubMed  PubMed Central  Google Scholar 

  7. Short NJ, Konopleva M, Kadia T et al (2021) An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol 96(7):E229–E232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Maiti A, Franquiz MJ, Ravandi F et al (2020) Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias. Acta Haematol 143(6):567–573

    Article  CAS  PubMed  Google Scholar 

  9. Fang DD, Zhu H, Tang Q et al (2021) FLT3 inhibition by olverem batinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. Transl Oncol 15(1):101244

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wang N, He J, Liu F (2022) Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B/myeloid mixed-phenotype acute leukemia and relapsed/refractory acute myeloid leukemia: a report of 3 cases. Chemotherapy 67(3):178–182

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported in part by grants from the National Natural Science Foundation of China [81970138, 81900130], Translational Research Grant of NCRCH (2020ZKMB05), Jiangsu Province “333” project, Social Development Project of the Science and Technology Department of Jiangsu (BE2021649), and Gusu Key Medical Talent Program (GSWS2019007).

Author information

Authors and Affiliations

  1. Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China

    Tongtong Zhang, Haixia Zhou, Mingzhu Xu, Chongsheng Qian, Aining Sun, Depei Wu & Shengli Xue

  2. Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215000, China

    Tongtong Zhang, Haixia Zhou, Mingzhu Xu, Chongsheng Qian, Aining Sun, Depei Wu & Shengli Xue

Authors
  1. Tongtong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haixia Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mingzhu Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chongsheng Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aining Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Depei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shengli Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shengli Xue.

Ethics declarations

Ethics approval

This study has completely complied with the human research regulations and ethical requirements issued by the Ethics Committee of the First Affiliated Hospital of Soochow University.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflicts of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Tongtong Zhang and Haixia Zhou contributed equally to this work and should be considered co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, T., Zhou, H., Xu, M. et al. Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia. Ann Hematol 102, 973–975 (2023). https://doi.org/10.1007/s00277-023-05110-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05110-y

Search

Navigation